This guidance is intended to assist clinical investigators, sponsors, and sponsor-investigators in determining whether human research studies must be conducted under an investigational new drug application (IND), as described in Title 21 of the Code of Federal Regulations, part 312 (21 CFR part 312) (the IND regulations). This guidance describes when an IND is required, specific situations in which an IND is not required, and a range of issues that, in FDA’s experience, have been the source of confusion or misperceptions about the application of the IND regulations.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM229175.pdf
Most Recent Guidances (All Agencies)
- FDA proposes draft guidelines intended to improve the representation of women in medical device clinical studies
- S2 R1
- Good Laboratory Practice for Nonclinical Laboratory Studies
- Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination
- Investigational New Drug Applications (INDs)— Determining Whether Human Research Studies Can Be Conducted Without an IND
